Maximilian Witzel

发表

Gene therapy for Wiskott–Aldrich syndrome

C. Klein, Christian J Braun, K. Boztug, 2013 .

Gene therapy for Wiskott-Aldrich syndrome-long - Term efficacy and genotoxicity (Science Translational Medicine)

D. Steinemann, A. Schambach, W. Al-Herz, 2014 .

Myb‐like, SWIRM, and MPN domains 1 (MYSM1) deficiency: Genotoxic stress‐associated bone marrow failure and developmental aberrations

D. Steinemann, J. Puchalka, W. Al-Herz, 2017, The Journal of allergy and clinical immunology.

The Mutation of CD27 Deficiency Presented With Familial Hodgkin Lymphoma and a Review of the Literature

Ekrem Ünal, Maximilian Witzel, C. Klein, 2022, Journal of pediatric hematology/oncology.

Gene therapy for Wiskott-Aldrich Syndrome—Long-term reconstitution and clinical benefits, but increased risk for leukemogenesis

C. von Kalle, C. Klein, Manfred Schmidt, 2014, Rare diseases.

Involvement of α 1‐2‐fucosyltransferase I (FUT1) and surface‐expressed lewisy (CD174) in first endothelial cell–cell contacts during angiogenesis

H. Goldschmidt, R. Grobholz, A. Greiner, 2008, Journal of cellular physiology.

Retrieval of vector integration sites from cell-free DNA

F. Bushman, A. Fischer, C. Klein, 2021, Nature Medicine.

Gene Therapy for Wiskott-Aldrich Syndrome—Long-Term Efficacy and Genotoxicity

Michael Rothe, Christof von Kalle, Raffaele Fronza, 2014, Science Translational Medicine.

Chromatin-remodeling factor SMARCD2 regulates transcriptional networks controlling differentiation of neutrophil granulocytes

A. Schäffer, J. Gagneur, E. Wolf, 2017, Nature Genetics.

Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia

C. von Kalle, S. Fröhling, E. Schröck, 2020, Leukemia.